Iptacopan: First Approval.
Syed YY.
Drugs · review; journal article · DOI 10.1007/s40265-024-02009-4 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för iptacopan. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
17 hitsOral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R, Röth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Höchsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM.
N Engl J Med · journal article · DOI 10.1056/nejmoa2308695A new alternative: inhibiting complement activation in patients with IgA nephropathy.
Floege J.
Kidney Int · comment; journal article · DOI 10.1016/j.kint.2023.10.012Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J.
Kidney Int · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.kint.2023.09.027Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Vivarelli M, Bomback AS, Meier M, Wang Y, Webb NJA, Veldandi UK, Smith RJH, Kavanagh D.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2023.10.022Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Wong E, Nester C, Cavero T, Karras A, Le Quintrec M, Lightstone L, Eisenberger U, Soler MJ, Kavanagh D, Daina E, Praga M, Medjeral-Thomas NR, Gäckler A, Garcia-Carro C, Biondani A, Chaperon F, Kulmatycki K, Milojevic J, Webb NJA, Nidamarthy PK, Junge G, Remuzzi G.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2023.09.017Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro Studies.
James AD, Kulmatycki K, Poller B, Romeo AA, Van Lier JJ, Klein K, Pearson D.
Drug Metab Dispos · research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.123.001290Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D, Greenbaum LA, Bagga A, Karki RG, Chen CW, Vasudevan S, Charney A, Dahlke M, Fakhouri F.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2023.04.029Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV, Rovin BH, Zhang H, Kashihara N, Maes B, Trimarchi H, Perkovic V, Meier M, Kollins D, Papachristofi O, Charney A, Barratt J.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2023.01.041The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria.
Han B, Ji J, Zhang B, Bai H, Zhou D, Feng F, Huang Y, Zhu H, Chen L, Wu Z, Jiang X, Li X, Jia Q, Chang Q, Pan H, Peng H, Zheng W, Huang H, Chen Z, Yang C, Chen M, Du B, Zhang S.
Ann Hematol · letter · DOI 10.1007/s00277-022-04933-5Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, Trapani AJ, Smith RJH.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2022.07.004Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
Jang JH, Wong L, Ko BS, Yoon SS, Li K, Baltcheva I, Nidamarthy PK, Chawla R, Junge G, Yap ES.
Blood Adv · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1182/bloodadvances.2022006960Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
Chen K, Deng Y, Shang S, Tang L, Li Q, Bai X, Chen X.
Biomed Pharmacother · journal article · DOI 10.1016/j.biopha.2022.113433Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R.
Lancet Haematol · clinical trial, phase ii; multicenter study; journal article · DOI 10.1016/s2352-3026(21)00028-4Pharmacokinetics and metabolism of LNP023 in rats by liquid chromatography combined with electrospray ionization-tandem mass spectrometry.
Jiang X, Pan R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.5006Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.
Mainolfi N, Ehara T, Karki RG, Anderson K, Mac Sweeney A, Liao SM, Argikar UA, Jendza K, Zhang C, Powers J, Klosowski DW, Crowley M, Kawanami T, Ding J, April M, Forster C, Serrano-Wu M, Capparelli M, Ramqaj R, Solovay C, Cumin F, Smith TM, Ferrara L, Lee W, Long D, Prentiss M, De Erkenez A, Yang L, Liu F, Sellner H, Sirockin F, Valeur E, Erbel P, Ostermeier D, Ramage P, Gerhartz B, Schubart A, Flohr S, Gradoux N, Feifel R, Vogg B, Wiesmann C, Maibaum J, Eder J, Sedrani R, Harrison RA, Mogi M, Jaffee BD, Adams CM.
J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.9b01870Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J.
Proc Natl Acad Sci U S A · research-article; journal article · DOI 10.1073/pnas.1820892116